Shandong province’s draft pharmaceutical industry development action plan (’15th Five-Year’, soliciting comments) calls for accelerated development and industrialization of monoclonal antibodies, bispecific and trispecific antibodies, antibody-drug conjugates (ADCs), recombinant proteins, cell and gene therapies, innovative vaccines and marine biopharmaceuticals, targeting major infectious, respiratory, oncologic, drug‑resistant, autoimmune, metabolic and CNS diseases. The plan flags antibody th

Shandong province’s draft pharmaceutical industry development action plan (’15th Five-Year’, soliciting comments) calls for accelerated development and industrialization of monoclonal antibodies, bispecific and trispecific antibodies, antibody-drug conjugates (ADCs), recombinant proteins, cell and gene therapies, innovative vaccines and marine biopharmaceuticals, targeting major infectious, respiratory, oncologic, drug‑resistant, autoimmune, metabolic and CNS diseases. The plan flags antibody therapies for malignant tumors, hematologic, autoimmune, metabolic, ophthalmic, neurological, cardiovascular and anti‑infective indications as priorities and backs development of multifunctional antibodies, antibody‑fusion proteins, nanobodies, antibody combinations and compound formulations, high‑concentration products and novel ADC platforms to strengthen core technologies and industrial capacity.